Portal de Periódicos da CAPES

A study on p16, pRb, cdk4 and cyclinD1 expression in non-small cell lung cancers

1998; Elsevier BV; Volume: 130; Issue: 1-2 Linguagem: Inglês

10.1016/s0304-3835(98)00115-3

1872-7980

Lingfei Kong, Ying Pingzhang, Zhengguo Liu, Gen Jianhua, Zhao Yao-wu,

RNA modifications and cancer

To observe the expression of p16, pRb, cdk4 and cyclinD1 in non-small cell lung cancers, 104 cases of resected lung cancers were collected, which included squamous cell carcinomas, adenocarcinomas and large cell carcinomas. Immunohistochemistry assay was carried out. The results showed that 67% of squamous cell carcinomas and 46% of adenocarcinomas expressed p16, 64% of squamous cell carcinomas and 85% of adenocarcinomas expressed pRb and 66% of cancers expressed p16 or pRb. About 70% of the tumors expressed cyclinD1. More than 90% of the tumors expressed cdk4 and there was an increased trend with decreasing differentiation of both squamous cell carcinomas and adenocarcinomas. Sixty-seven percent of the highly differentiated and 100% of the poorly differentiated squamous cell carcinomas expressed cdk4. The aberrant p16 and pRb gene product expression played a significant role in the development and histological subtype of lung cancers by conditioning the biological behavior of NSCLC. cdk4 was an important factor in histological differentiation.